Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|June 29, 2015
The Evolving Specialty Pharmacy Patient Experience
Author(s)Davy James, Managing Editor
Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses developing trends in the treatment of specialty pharmacy patients.
Advertisement
Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses developing trends in the treatment of specialty pharmacy patients.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
4
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
5